Goldman Sachs’s Sarepta Therapeutics SRPT Stock Holding History

Goldman Sachs’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-57,100	Closed	-$1.23M	–	6948
2025 Q4	$1.23M	Sell	57,100 -54,900	-49%	-$1.16M	﹤0.01%	4975
2025 Q3	$2.16M	Sell	112,000 -105,400	-48%	-$1.88M	﹤0.01%	4406
2025 Q2	$3.72M	Buy	217,400 +160,300	+281%	+$6.84M	﹤0.01%	3693
2025 Q1	$3.64M	Sell	57,100 -600	-1%	-$63.2K	﹤0.01%	3651
2024 Q4	$7.02M	Buy	57,700 +600	+1%	+$73.5K	﹤0.01%	3120
2024 Q3	$7.13M	Buy	+57,100	New	+$7.89M	﹤0.01%	3030
2023 Q2	–	Sell	-63,400	Closed	-$8.74M	–	6049
2023 Q1	$8.74M	Buy	63,400 +36,400	+135%	+$4.72M	﹤0.01%	2543
2022 Q4	$3.5M	Buy	+27,000	New	+$3.13M	﹤0.01%	3486
2022 Q1	–	Sell	-55,500	Closed	-$5M	–	6893
2021 Q4	$5M	Hold	55,500	–	–	﹤0.01%	3410
2021 Q3	$5.13M	Hold	55,500	–	–	﹤0.01%	3342
2021 Q2	$4.32M	Sell	55,500 -6,600	-11%	-$500K	﹤0.01%	3468
2021 Q1	$4.63M	Sell	62,100 -115,300	-65%	-$10.6M	﹤0.01%	3203
2020 Q4	$30.2M	Buy	177,400 +93,700	+112%	+$13.9M	0.01%	1514
2020 Q3	$11.8M	Sell	83,700 -24,600	-23%	-$3.74M	﹤0.01%	2177
2020 Q2	$17.4M	Sell	108,300 -117,400	-52%	-$16M	0.01%	1804
2020 Q1	$22.1M	Buy	225,700 +62,900	+39%	+$7.19M	0.01%	1433
2019 Q4	$21M	Buy	162,800 +66,500	+69%	+$6.71M	0.01%	1817
2019 Q3	$7.25M	Buy	96,300 +6,500	+7%	+$768K	﹤0.01%	2568
2019 Q2	$13.6M	Buy	89,800 +41,400	+86%	+$5.03M	﹤0.01%	2141
2019 Q1	$5.77M	Buy	48,400 +38,400	+384%	+$4.94M	﹤0.01%	2857
2018 Q4	$1.09M	Sell	10,000 -27,700	-73%	-$3.46M	﹤0.01%	3911
2018 Q3	$6.09M	Buy	37,700 +27,700	+277%	+$3.79M	﹤0.01%	2838
2018 Q2	$1.32M	Buy	+10,000	New	+$943K	﹤0.01%	3890
2018 Q1	–	Sell	-40,000	Closed	-$2.23M	–	6372
2017 Q4	$2.23M	Sell	40,000 -225,700	-85%	-$12M	﹤0.01%	3698
2017 Q3	$12.1M	Buy	+265,700	New	+$10.6M	﹤0.01%	2416
2017 Q1	–	Sell	-113,000	Closed	-$3.1M	–	6991
2016 Q4	$3.1M	Sell	113,000 -160,000	-59%	-$6.43M	﹤0.01%	3456
2016 Q3	$16.8M	Buy	273,000 +233,400	+589%	+$7.06M	0.01%	2041
2016 Q2	$755K	Buy	39,600 +11,800	+42%	+$219K	﹤0.01%	4453
2016 Q1	$543K	Sell	27,800 -133,700	-83%	-$2.34M	﹤0.01%	4666
2015 Q4	$6.23M	Buy	161,500 +40,000	+33%	+$1.3M	﹤0.01%	2636
2015 Q3	$3.9M	Buy	121,500 +117,500	+2,938%	+$3.99M	﹤0.01%	3108
2015 Q2	$122K	Sell	4,000 -33,400	-89%	-$683K	﹤0.01%	6508
2015 Q1	$497K	Buy	+37,400	New	+$499K	﹤0.01%	5137
2014 Q4	–	Sell	-328,200	Closed	-$6.92M	–	7305
2014 Q3	$6.92M	Buy	+328,200	New	+$7.41M	﹤0.01%	2701
2014 Q2	–	Sell	-50,000	Closed	-$1.2M	–	7135
2014 Q1	$1.2M	Sell	50,000 -215,900	-81%	-$5.5M	﹤0.01%	4490
2013 Q4	$5.42M	Buy	265,900 +94,800	+55%	+$2.82M	﹤0.01%	2995
2013 Q3	$8.08M	Buy	+171,100	New	+$6.59M	﹤0.01%	2461

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's SRPT Position: Q1 2026 in Review

Goldman Sachs increased its Sarepta Therapeutics (SRPT) stake by 91% in Q1 2026, buying an estimated $9.96M and bringing the position to 1,078,252 shares worth $23.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2286.

Goldman Sachs first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $201M in Q2 2020. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

Goldman Sachs held 1,078,252 shares of Sarepta Therapeutics worth $23.5M as of Q1 2026.
Goldman Sachs bought 514,766 Sarepta Therapeutics shares in Q1 2026, an estimated $9.96M.
Sarepta Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2286 holding.
Goldman Sachs first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
Goldman Sachs's Sarepta Therapeutics position peaked at $201M in Q2 2020.
339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.